المؤلفون: Kocanci, Fatma Gonca¹ (AUTHOR) gonca.kocanci@alanya.edu.tr, Erol, Azize Yasemin Goksu^2,3 (AUTHOR) yaseminerol@akdeniz.edu.tr, Yildiz, Fatma¹ (AUTHOR), Eciroglu, Hamiyet¹ (AUTHOR)

المصدر: Scandinavian Journal of Immunology. Jan2024, Vol. 99 Issue 1, p1-12. 12p.

مصطلحات موضوعية: *HYDROGEN peroxide, *PIMECROLIMUS, *OXIDANT status, *MICROGLIA, *ANTIOXIDANTS

المؤلفون: Chu, Chia-Yu¹ (AUTHOR), Yao, Tsung-Chieh² (AUTHOR), Shih, I.-Hsin³ (AUTHOR), Yang, Chin-Yi^3,4 (AUTHOR), Chin, Chan Lee⁵ (AUTHOR), Ibrahim, Sabeera Begum Binti Kader⁶ (AUTHOR), Thevarajah, Suganthi⁶ (AUTHOR), Fon, Leong Kin⁷ (AUTHOR), Ho, Marco Hok-Kung⁸ (AUTHOR), Mo, Chow Chung⁹ (AUTHOR), Yu, Chow Pok⁸ (AUTHOR), Loo, Steven King-Fan¹⁰ (AUTHOR), Luger, Thomas¹¹ (AUTHOR) luger@uni-muenster.de

المصدر: Dermatology & Therapy. Mar2023, Vol. 13 Issue 3, p717-727. 11p.

مصطلحات موضوعية: *ATOPIC dermatitis, *PIMECROLIMUS, *CHILD patients, *INFANTS, *ASIANS, *BURNING mouth syndrome, *PEDIATRIC dermatology

مصطلحات جغرافية: PACIFIC Area

المؤلفون: Dou, Xia¹ (AUTHOR) douxiaderm@163.com, Liu, Lingling¹ (AUTHOR), Zhu, Xuejun¹ (AUTHOR), Wen, Weijing¹ (AUTHOR), Ni, Chunya¹ (AUTHOR), Zhao, Yi¹ (AUTHOR), He, Zhixin² (AUTHOR), Li, Hongchun² (AUTHOR), Sun, Qiuning² (AUTHOR), Yang, Qinping³ (AUTHOR), Sun, Xinfen³ (AUTHOR), Guo, Yifeng⁴ (AUTHOR)

المصدر: Journal of Dermatological Treatment. 2023, Vol. 34 Issue 1, p1-7. 7p.

مصطلحات موضوعية: *ATOPIC dermatitis, *PIMECROLIMUS, *INFANTS, *ASIANS, *RACE

مصطلحات جغرافية: CHINA

المؤلفون: Brinia, Chrysa, Tsiogka, Aikaterini, Platsidaki, Eftychia, Markantoni, Vasiliki, Gregoriou, Stamatios, Rigopoulos, Dimitris, Kontochristopoulos, Georgios

المصدر: Dermatology Online Journal. 29(3)

مصطلحات موضوعية: amicrobial, dapsone, pimecrolimus, pustulosis, treatment

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/71h6f05cTest

المؤلفون: Azizzadeh, Maryam¹ (AUTHOR), Pahlevan, Daryoush² (AUTHOR) dshpahlevan@gmail.com, Bagheri, Bahador^3,4 (AUTHOR)

المصدر: Clinical & Experimental Dermatology. May2022, Vol. 47 Issue 5, p926-931. 6p. 1 Diagram, 5 Charts.

مصطلحات موضوعية: *PIMECROLIMUS, *SKIN inflammation, *PATIENT satisfaction, *SAFETY

المؤلفون: Aikaterini Zacharopoulou, Aikaterini Tsiogka, Antonios Tsimpidakis, Androniki Lamia, Dimitra Koumaki, Stamatios Gregoriou

المصدر: Journal of Clinical Medicine, Vol 13, Iss 11, p 3267 (2024)

مصطلحات موضوعية: tinea incognito, fungal infection, dermatophyte infection, corticosteroid, tacrolimus, pimecrolimus, Medicine

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2077-0383/13/11/3267Test; https://doaj.org/toc/2077-0383Test

الوصول الحر: https://doaj.org/article/c82d0be49194438ab2743f91f433c56eTest

المؤلفون: Zhao, Zuotao¹ (AUTHOR), Gao, Xing-Hua² (AUTHOR), Li, Wei³ (AUTHOR), Wang, Hua⁴ (AUTHOR), Liang, Yunsheng⁵ (AUTHOR), Tang, Jianping⁶ (AUTHOR), Yao, Xu⁷ (AUTHOR), Zhao, Hua⁸ (AUTHOR), Luger, Thomas⁹ (AUTHOR) luger@uni-muenster.de

المصدر: Dermatology & Therapy. Apr2022, Vol. 12 Issue 4, p933-947. 15p.

مصطلحات موضوعية: *ATOPIC dermatitis, *PIMECROLIMUS, *DISEASE prevalence, *CALCINEURIN, *SKIN diseases

مصطلحات جغرافية: CHINA

الشركة/الكيان: TATA Consultancy Services Ltd.

المؤلفون: Nofal, Ahmad¹ (AUTHOR) ahmadnofal5@hotmail.com, Eldeeb, Fatma¹ (AUTHOR), Shalaby, Mona¹ (AUTHOR), Al‐Balat, Waleed¹ (AUTHOR)

المصدر: Dermatologic Therapy. Mar2022, Vol. 35 Issue 3, p1-6. 6p.

مصطلحات موضوعية: *VITILIGO, *PIMECROLIMUS, *FLUOROURACIL, *COMPARATIVE studies, *HYPERPIGMENTATION

المؤلفون: Kamilla E. Efendieva, Leyla S. Namazova-Baranova, Juliya G. Levina, Vera G. Kalugina, Anna A. Alekseeva, Elena A. Vishneva, Konstantin S. Volkov, К. Е. Эфендиева, Л. С. Намазова-Баранова, Ю. Г. Левина, В. Г. Калугина, А. А. Алексеева, Е. А. Вишнева, К. С. Волков

المصدر: Current Pediatrics; Том 22, № 6 (2023); 513-520 ; Вопросы современной педиатрии; Том 22, № 6 (2023); 513-520 ; 1682-5535 ; 1682-5527

مصطلحات موضوعية: пимекролимус, children, calcineurin inhibitor, pimecrolimus, дети, ингибиторы кальциневрина

وصف الملف: application/pdf

العلاقة: https://vsp.spr-journal.ru/jour/article/view/3354/1348Test; Атопический дерматит у детей: клинические рекомендации / Российское общество дерматовенерологов и косметологов; Российская ассоциация аллергологов и клинических иммунологов; Союз педиатров России. — Минздрав России; 2021. — 81 с.; Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: https://doi.org/10.1111/jdv.18429Test; Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: https://doi.org/10.1016/S0140-6736Test(20)31286-1; Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. doi: https://doi.org/10.2340/00015555-3510Test; Dogruel D, Bingol G, Altintas DU, et al. Prevalence of and risk factors for atopic dermatitis: a birth cohort study of infants in southeast Turkey. Allergol Immunopathol (Madr). 2016;44(3): 214–220. doi: https://doi.org/10.1016/j.aller.2015.07.002Test; Wartna JB, Moed H, van Alphen EI, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2):143–150. doi: https://doi.org/10.3109/02813432.2016.1160629Test; Weber A, Herr C, Hendrowarsito L, et al. No further increase in the parent reported prevalence of allergies in Bavarian preschool children: Results from three cross-sectional studies. Int J Hyg Environ Health. 2016;219(4-5):343–348. doi: https://doi.org/10.1016/j.ijheh.2016.02.001Test; Montefort S, Ellul P, Montefort M, et al. Increasing prevalence of asthma, allergic rhinitis but not eczema in 5- to 8-yr-old Maltese children (ISAAC). Pediatr Allergy Immunol. 2009;20(1):67–71. doi: https://doi.org/10.1111/j.1399-3038.2008.00746.xTest; Napolitano M, Fabbrocini G, Martora F, et al. Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35(12):e15901. doi: https://doi.org/10.1111/dth.15901Test; Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124(6):1251–1258.e23. doi: https://doi.org/10.1016/j.jaci.2009.10.009Test; Mallol J, Crane J, von Mutius E, et al. The international study of asthma and allergies in childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73–85. doi: https://doi.org/10.1016/j.aller.2012.03.001Test; Kleiner A, Flohr C, Weiland S, et al. International variation in prevalence of flexural eczema and atopic sensitization. Results from phase two of the International Study of Asthma and Allergies in Childhood (ISAAC Phase Two). Allergo J. 2008;17(1):79–81.; Pesce G, Marcon A, Carosso A, et al. Adult eczema in Italy: prevalence and associations with environmental factors. J Eur Acad Dermatol Venereol. 2015;29(6):1180–1187. doi: https://doi.org/10.1111/jdv.12784Test; Theodosiou G, Montgomery S, Metsini A, et al. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol. 2019;99(11):964–970. doi: https://doi.org/10.2340/00015555-3257Test; Котова Е.Г., Кобякова О.С., Александрова Г.А. и др. Общая заболеваемость детского населения России (0–14 лет) в 2022 году: статистические материалы. — М.: ЦНИИОИЗ Минздрава России; 2023.; Намазова-Баранова Л.С. Аллергия у детей: от теории — к практике. — М.: Союз педиатров России; 2011.; Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537): 733–743. doi: https://doi.org/10.1016/S0140-6736Test(06)69283-0; Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: https://doi.org/10.1038/s41572-018-0001-zTest; Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387:1109–1122. doi: https://doi.org/10.1016/S0140-6736Test(15)00149-X; Torres T, Ferreira EO, Gonçalo M, et al. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606–613. doi: https://doi.org/10.20344/amp.11963Test; Apfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema: population‐based cross‐sectional study in Germany. Allergy. 2011;66(2):206–213. doi: https://doi.org/10.1111/j.1398-9995.2010.02464.xTest; Атопический дерматит у детей: клинические рекомендации / Союз педиатров России; Российская ассоциация аллергологов и клинических иммунологов; Российское общество дермато-венерологов и косметологов. — Минздрав России; 2016. — 60 с.; Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14): 1315–1327. doi: https://doi.org/10.1056/NEJMra1011040Test; Juul-Dam M, Sejersen H, Vestergaard C, et al. The impact of filaggrin genotype and atopic dermatitis on risk and severity of keratoconus. J EuCornea. 2020;7:4–7. doi: https://doi.org/10.1016/j.xjec.2020.02.001Test; Paternoster L, Standl M, Waage J, et al. Multi‐ancestry genome‐wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449–1456. doi: https://doi.org/10.1038/ng.3424Test; South AP, Cabral A, Ives JH, et al. Human epidermal differentiation complex in a single 2.5 Mbp long continuum of overlapping DNA cloned in bacteria integrating physical and transcript maps. J Invest Dermatol. 1999;112(6):910–918. doi: https://doi.org/10.1046/j.1523-1747.1999.00613.xTest; Stemmler S, Hoffjan S. Trying to understand the genetics of atopic dermatitis. Mol Cell Probes. 2016;30(6):374–385. doi: https://doi.org/10.1016/j.mcp.2016.10.004Test; Halling-Overgaard AS, Kezic S, Jakasa I, et al. Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol. 2017;177(1):84–106. doi: https://doi.org/10.1111/bjd.15065Test; Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433. doi: https://doi.org/10.1007/s11882-014-0433-9Test; Kamata Y, Tominaga M, Takamori K. Itch in atopic dermatitis management. Curr Probl Dermatol. 2016;50:86–93. doi: https://doi.org/10.1159/000446048Test; Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 2009;129(8):1878–1891. doi: https://doi.org/10.1038/jid.2009.71Test; Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017; 140(3):633–643. doi: https://doi.org/10.1016/j.jaci.2017.07.006Test; Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110. doi: https://doi.org/10.4172/2155-9899.1000110Test; Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067-1070. doi: https://doi.org/10.1038/jid.2008.88Test; Totte JE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687-695. doi: https://doi.org/10.1111/bjd.14566Test; Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-859. doi: https://doi.org/10.1101/gr.131029.111Test; Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017; 9(378):eaah4680. doi: https://doi.org/10.1126/scitranslmed.aah4680Test; Myles IA, Earland NJ, Anderson ED, et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3(9):e120608. doi: https://doi.org/10.1172/jci.insight.120608Test; Siegels D, Haufe E, Heinrich L, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5: 274-286. doi: https://doi.org/10.5414/ALX02262ETest; Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925-931. doi: https://doi.org/10.1016/j.jaci.2004.01.778Test; von Kobyletzki LB, Bornehag CG, Breeze E, et al. Factors associated with remission of eczema in children: a population-based follow-up study. Acta Derm Venereol. 2014;94(2):179-184. doi: https://doi.org/10.2340/00015555-1681Test; Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291-297. doi: https://doi.org/10.1016/j.det.2017.02.003Test; Nissen SP, Kjaer HF, Host A, et al. The natural course of sensitization and allergic diseases from childhood to adulthood. Pediatr Allergy Immunol. 2013;24(6):549-555. doi: https://doi.org/10.1111/pai.12108Test; Luger T, Augustin M, Lambert J, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414-424. doi: https://doi.org/10.1111/pai.13422Test; Wollenberg A, Werfel T, Ring J, et al. Atopic Dermatitis in Children and Adults — Diagnosis and Treatment. Dtsch Arztebl Int. 2023;120(13):224-234. doi: https://doi.org/10.3238/arztebl.m2023.0011Test; Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012;129(5):1187-1197. doi: https://doi.org/10.1016/j.jaci.2012.02.036Test; Hui-Beckman JW, Goleva E, Berdyshev E, Leung DYM. Endotypes of atopic dermatitis and food allergy. J Allergy Clin Immunol. 2023; 151(1):26-28. doi: https://doi.org/10.1016/j.jaci.2022.07.021Test; Flohr C, Perkin M, Logan K, et al. Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants. J Invest Dermatol. 2014;134(2):345-350. doi: https://doi.org/10.1038/jid.2013.298Test; Spergel JM, Boguniewicz M, Schneider L, et al. Food allergy in infants with atopic dermatitis: limitations of food-specific IgE measurements. Pediatrics. 2015;136(6):e1530-e1538. doi: https://doi.org/10.1542/peds.2015-1444Test; Roduit C, Frei R, Depner M, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171(7):655-662. doi: https://doi.org/10.1001/jamapediatrics.2017.0556Test; Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. doi: https://doi.org/10.1016/j.jaad.2009.11.011Test; Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4): 818-823. doi: https://doi.org/10.1016/j.jaci.2014.08.005Test; Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824-830.e6. doi: https://doi.org/10.1016/j.jaci.2014.07.060Test; Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet. 2020;395(10228):962-972. doi: https://doi.org/10.1016/S0140-6736Test(19)32984-8; Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet. 2020;395(10228):951-961. doi: https://doi.org/10.1016/S0140-6736Test(19)32983-6; Paller AS, Spergel JM, Mina-Osorio P, et al. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46-55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Test; Schneider L, Hanifin J, Boguniewicz M, et al. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016;33(4):388-398. doi: https://doi.org/10.1111/pde.12867Test; Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475-1482. doi: https://doi.org/10.1111/all.12049Test; Wan J, Mitra N, Hoffstad OJ, et al. Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study. J Am Acad Dermatol. 2017;77(4): 634-640. doi: https://doi.org/10.1016/j.jaad.2017.06.013Test; Gough H, Grabenhenrich L, Reich A, et al. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol. 2015;26(5):431-437. doi: https://doi.org/10.1111/pai.12410Test; Grabenhenrich LB, Keil T, Reich A, et al. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol. 2015;136(4):932-940.e12. doi: https://doi.org/10.1016/j.jaci.2015.03.040Test; Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25. doi: https://doi.org/10.1016/j.jid.2016.08.022Test; Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy. 2010;65(12):1506-1524. doi: https://doi.org/10.1111/j.1398-9995.2010.02449.xTest; Ivert LU, Wahlgren CF, Lindelof B, et al. Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol. 2021;185(2):335-342. doi: https://doi.org/10.1111/bjd.19624Test; Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018;19(6):821-838. doi: https://doi.org/10.1007/s40257-018-0383-4Test; Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis. J Cosmet Dermatol. 2020;19(8):2016-2020. doi: https://doi.org/10.1111/jocd.13263Test; Ariens LFM, van Nimwegen KJM, Shams M, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9):762-768. doi: https://doi.org/10.2340/00015555-3212Test; Eckert L, Gupta S, Gadkari A, et al. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195. doi: https://doi.org/10.1016/j.jaad.2019.03.037Test; Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):281-288. doi: https://doi.org/10.1016/j.iac.2010.05.004Test; Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. doi: https://doi.org/10.1038/jid.2014.530Test; Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol. 2017;176(5):1170-1178. doi: https://doi.org/10.1111/bjd.15280Test; Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi: https://doi.org/10.1111/jdv.14891Test; Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: https://doi.org/10.1111/jdv.14888Test; Giam YC, Hebert AA, Dizon MV, et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6(2): 120-128. doi: https://doi.org/10.5415/apallergy.2016.6.2.120Test; Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10(7):744-749.; Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. Am J Clin Dermatol. 2015;16(5):341-359. doi: https://doi.org/10.1007/s40257-015-0146-4Test; Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. doi: https://doi.org/10.1111/jdv.16892Test; Coureau B, Bussieres JF, Tremblay S. Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids. Ann Pharmacother. 2008;42(12):1903-1907. doi: https://doi.org/10.1345/aph.1L067Test; Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56: 211-216. doi: https://doi.org/10.1016/j.jaad.2006.05.073Test; Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis. A systematic review. JAMA Dermatol. 2017;153(10):1036-1042. doi: https://doi.org/10.1001/jamadermatol.2017.2437Test; Bos B, Antonescu I, Osinga H, et al. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. Pediatr Dermatol. 2019;36(1): 100-104. doi: https://doi.org/10.1111/pde.13698Test; Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatolog Treat. 2017;28(2):104-111. doi: https://doi.org/10.1080/09546634.2016.1201189Test; Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333-343. doi: https://doi.org/10.1159/000484407Test; Gutfreund K, Bienias W, Szewczyk A, Kaszuba A. Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165-169. doi: https://doi.org/10.5114/pdia.2013.35619Test; Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus — an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13(12):721-730. doi: https://doi.org/10.1111/j.0906-6705.2004.00269.xTest; Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;124(3 Suppl 2): R19-R28. doi: https://doi.org/10.1016/j.jaci.2009.07.015Test; Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142(2):155-162. doi: https://doi.org/10.1067/mpd.2003.65Test; Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: https://doi.org/10.1542/peds.2014-1990Test; Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110(2): 277-284. doi: https://doi.org/10.1067/mai.2002.126500Test; Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-131. doi: https://doi.org/10.2165/00128071-200607020-00005Test; Luger T, Paller AS, Irvine AD, et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol. 2021;35(7):1505-1518. doi: https://doi.org/10.1111/jdv.17272Test; Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52(2): 240-246. doi: https://doi.org/10.1016/j.jaad.2004.09.016Test; van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565-569. doi: https://doi.org/10.1016/j.jaci.2007.05.042Test; Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73. doi: https://doi.org/10.1016/j.jaad.2007.06.041Test; Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92(5): 455-461. doi: https://doi.org/10.2340/00015555-1360Test; Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79(1):65-72.; Sunderkötter C, Weiss JM, Bextermöller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges. 2006;4(4):301-306. doi: https://doi.org/10.1111/j.1610-0387.2006.05932.xTest; Staab D, Kaufmann R, Brautigam M, Wahn U. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents‘ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16(6):527-533. doi: https://doi.org/10.1111/j.1399-3038.2005.00306.xTest; Gollnick H, Luger T, Freytag S, Brautigam M. StabiEL: stabilization of skin condition with Elidel — a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol. 2008;22(11):1319-1325. doi: https://doi.org/10.1111/j.1468-3083.2008.02807.xTest; https://vsp.spr-journal.ru/jour/article/view/3354Test

الإتاحة: https://doi.org/10.15690/vsp.v22i6.2666Test
https://doi.org/10.1111/jdv.18429Test
https://doi.org/10.1016/S0140-6736Test(20)31286-1
https://doi.org/10.2340/00015555-3510Test
https://doi.org/10.1016/j.aller.2015.07.002Test
https://doi.org/10.3109/02813432.2016.1160629Test
https://doi.org/10.1016/j.ijheh.2016.02.001Test
https://doi.org/10.1111/j.1399-3038.2008.00746.xTest
https://doi.org/10.1111/dth.15901Test
https://doi.org/10.1016/j.jaci.2009.10.009Test

المؤلفون: Xia Dou, Lingling Liu, Xuejun Zhu, Weijing Wen, Chunya Ni, Yi Zhao, Zhixin He, Hongchun Li, Qiuning Sun, Qinping Yang, Xinfen Sun, Yifeng Guo

المصدر: Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)

مصطلحات موضوعية: atopic dermatitis, pimecrolimus, topical corticosteroids, topical calcineurin inhibitors, china, Dermatology, RL1-803

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/0954-6634Test; https://doaj.org/toc/1471-1753Test

الوصول الحر: https://doaj.org/article/96748026c00243a9918cdf6e957e15b8Test